Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes

Journal of Child Neurology

Volumn 21, Issue 1, 2006, Pages 70-74

  Mujgan Sonmez, Fatma ^a   Demir, Ercan ^a   Orem, Asim ^a   Yildirmis, Sermet ^a   Orhan, Fazil ^a   Aslan, Adnan ^a   Topbas, Murat ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHENOBARBITAL; TRIACYLGLYCEROL; VALPROIC ACID;

ADOLESCENT; AGE; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EPILEPSY; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ALKALINE PHOSPHATASE; ANTICONVULSANTS; APOLIPOPROTEINS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; EPILEPSY; HUMANS; INFANT; LIPIDS; LIVER; PHENOBARBITAL; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRANSFERASES; VALPROIC ACID;

EID: 33646874537     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738060210011301     Document Type: Article

References (28)

1. Reynolds EH: Chronic antiepileptic toxicity: A review. Epilepsia 1975;16:319-352.
2. Matsuda I, Higashi A, Inotsume N: Physiologic and metabolic aspects of anticonvulsants. Pediatr Clin North Am 1989;36: 1099-1109.
3. Franzoni E, Govoni M, D'Addato S, et al: Total cholesterol, high-density lipoprotein cholesterol and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992;33:932-935.
4. Garcia RE, Moodie DS: Routine cholesterol surveillance in childhood. Pediatrics 1989;84:751-755.
5. Kark JD, Sandholzer C, Friedlander Y, et al: Plasma Lp(a), apolipoprotein (a) isoforms and acute myocardial infarction in men and women: A case-control study in the Jerusalem population. Atherosclerosis 1993;98:139-151.
6. Aynaci FM, Orhan F, Orem A, et al: Effect of antiepileptic drugs on plasma lipoprotein (a) and other lipid levels in childhood. J Child Neurol 2001;16:367-369.
7. Verrotti A, Basciani F, Domizio S, et al: Serum lipids and lipoproteins in patients with antiepileptic drugs. Pediatr Neurol 1998;19:364-367.
8. Schwaninger M, Ringleb P, Annecke A, et al: Elevated plasma concentrations of lipoprotein (a) in medicated epileptic patients. J Neurol 2000;247:687-690.
9. Tumer L, Serdaroglu A, Hasanoglu A, et al: Plasma homocysteine and lipoprotein (a) levels as risk factors for atherosclerotic vascular disease in epileptic children taking anticonvulsants. Acta Paediatr 2002;91:923-926.
10. Brämswig S, Sudhop T, Luers C, et al: Lipoprotein (a) concentration increases during treatment with carbamazepine. Epilepsia 2003;44:457-460.
11. Hobbs HH, White AL: Lipoprotein (a) intrigues and insights. Curr Opin Lipidol 1999;10:225-236.
12. Erem C, Deger O, Bostan M, et al: Plasma lipoprotein (a) concentrations in hypothyroid, euthyroid and hyperthyroid subjects. Acta Cardiol 1999;54:77-81.
13. Eiris-Punal J, Del Rio-Garma M, Del Rio-Garma MC, et al: Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999;40:1761-1766.
14. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
15. Isojarvi JI, Laatikainen TJ, Knip M, et al: Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
16. Isojarvi JI, Rathya J, Myllyla VV, et al: Valproate, lamotrigine and insulin mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
17. Conover CA, Lee PD, Kanaley JA, et al: Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992;74:1355-1360.
18. Sing A, Hamilton-Fairley D, Koistinen R, et al: Effect of insulin-like growth factor type-1 (IGF-1) and insulin on the secretion of sex hormone binding globulin and IGF-1 binding protein (IBP-1) by human hepatoma cells. J Endocrinol 1990;124:R1-R3.
19. Dahlen G, Slunga L, Lindblom B: Importance of LP(a) lipoprotein and HLA genotypes in atherosclerosis and diabetes. Clin Genet 1994;46:46-51.
20. Dahlen GH: Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-126.
21. Mackinnon LT, Hubinger L, Lepre F: Effects of physical activity and diet on lipoprotein (a). Med Sci Sports Exerc 1997;29: 1429-1436.
22. Eiris JM, Lojo S, Del Rio MC, et al: Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995;45:1155-1157.
23. Heldenberg D, Harel S, Holtzman M, et al: The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology 1983;33:510-513.
24. Reddy MN: Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 1985;180:359-363.
25. Utermann G, Menzel HJ, Kraft HG, et al: Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458-465.
26. O'Neill B, Callaghan N, Stapleton M, Molloy W: Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin. Acta Neurol Scand 1982;65:104-109.
27. Yalcin E, Hassanzadeh A, Mawlud K: The effects of long-term anticonvulsive treatment on serum lipid profile. Acta Paediatr Jpn 1997;39:342-345.
28. Zeitlhofer J, Doppelbauer A, Tribl G, et al: Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Invest 1993;71:574-578.